Developer docs
API playgroundTry for free, no card

Search company profiles

Baxalta

Full company profile

uuid000y52n

Namestring
Baxalta
Websiteurl
baxalta.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Baxalta Incorporated was a global biopharmaceutical company that developed and commercialized specialty therapeutics for patients with hematologic, immunologic, and oncologic conditions. Founded in 2014 and headquartered in Illinois, United States, the company operated as a publicly traded entity on the NYSE under ticker BXLT and was characterized as a $6 billion global biopharmaceutical leader with more than 10,000 employees.

Baxalta's commercial portfolio centered on rare and serious disease therapeutics, with oncology as a strategic growth vertical. On July 23, 2015, the company acquired ONCASPAR (pegaspargase), a specialty biologic indicated for acute lymphoblastic leukemia, expanding its hematology/oncology franchise and reinforcing its positioning in orphan-indication therapeutics where clinical complexity and regulatory exclusivity support durable franchises.

The company monetized its portfolio through branded specialty pharmaceutical sales to hospitals, specialty pharmacies, and treatment centers, generating $6 billion in revenue at scale with 10,000+ employees. Baxalta was delisted from the NYSE following a corporate transaction, ending its standalone operating history and absorbing its assets and pipeline into a larger pharmaceutical parent.

Short descriptiontext

Baxalta was a $6 billion global biopharmaceutical company that developed and commercialized specialty therapeutics for hematology, immunology, and oncology conditions, serving patients and healthcare providers worldwide from its Illinois headquarters with 10,000+ employees.

Ownership categoryenum
Headcount rangeband
5,001–10,000
akta.pro rankint
HeadquartersIllinois City, United States
HQ citystring
Illinois City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
biopharmaceutical products, rare disease therapies, hematology treatments, immunology products, oncology biologics
Industry3 codes
1Plasma Fractionation & Purification Manufacturing
CodeHLAIAHAIPrimaryYes
2Plasma-Derived Therapeutics (immunoglobulins, albumin, clotting factors)
CodeHLAAAAAIPrimaryNo
3Rare Oncology & Hematologic Malignancy Therapies
CodeHLAIAIACPrimaryNo
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Specialty Biopharmaceuticals
Social media profiles1 record
Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Baxalta was a global biopharmaceutical company that developed, manufactured, and commercialized specialty biologic therapies for rare and underserved patient populations in hematology, immunology, and oncology. The company built a portfolio around hospital-administered biologic treatments such as ONCASPAR (pegaspargase) for acute lymphoblastic leukemia, distributing them to specialty healthcare providers worldwide.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1ONCASPAR (pegaspargase)
CategoryOncology biopharmaceuticals
Description

ONCASPAR (pegaspargase) is a biologic therapy used as a component of multi-agent chemotherapy regimens for patients with acute lymphoblastic leukemia (ALL). Following Baxalta's 2015 acquisition, it became part of the company's specialty hematology/oncology franchise distributed to hospitals and specialty oncology treatment centers.

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
1Alexion Pharmaceuticals
TypeDirect peer
Description

Alexion specialized in rare-disease therapeutics (complement-mediated diseases), making it a direct peer in the rare-disease specialty biopharmaceutical category.

2CSL Behring
TypeDirect peer
Description

CSL Behring is the global leader in plasma-derived therapeutics, directly competing with Baxalta in immunoglobulins, clotting factors, and specialty plasma products.

3BioMarin Pharmaceutical
TypeEmerging player
Description

BioMarin focuses on rare-disease therapeutics for serious genetic conditions, making it a comparable specialty biopharma peer with similar business-model dynamics.

4Octapharma
TypeDirect peer
Description

Octapharma is one of the largest privately held plasma fractionators globally, competing directly with Baxalta in immunoglobulin and coagulation-factor markets.

5Genzyme (Sanofi)
TypeBroad incumbent
Description

Sanofi's Genzyme unit operates a broad rare-disease specialty portfolio with overlapping rare hematology and immunology capabilities, competing with Baxalta across multiple indications.

6Swedish Orphan Biovitrum (Sobi)
TypeDirect peer
Description

Sobi is a European rare-disease biopharmaceutical company with significant overlap in hematology and immunology franchises, directly comparable to Baxalta's portfolio.

7Shire plc
TypeDirect peer
Description

Shire was the direct acquirer of Baxalta in 2016 and operated in the same rare-disease and specialty biopharmaceutical space, with overlapping hematology, immunology, and rare-disease franchises.

8Grifols
TypeDirect peer
Description

Grifols is a major plasma fractionator and specialty biopharmaceutical company with a directly overlapping plasma-derived therapeutics portfolio.

9Vertex Pharmaceuticals
TypeEmerging player
Description

Vertex develops specialty therapeutics for serious diseases including rare genetic disorders, sharing the high-priced, specialty-care commercial model of Baxalta.

10Bioverativ
TypeDirect peer
Description

Bioverativ focused on hemophilia and rare blood disorders before being acquired by Sanofi, directly overlapping Baxalta's hematology franchise.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment2 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Baxalta

Specialty Biopharmaceuticalsbaxalta.com

Baxalta was a $6 billion global biopharmaceutical company that developed and commercialized specialty therapeutics for hematology, immunology, and oncology conditions, serving patients and healthcare providers worldwide from its Illinois headquarters with 10,000+ employees.

What Baxalta does

Baxalta Incorporated was a global biopharmaceutical company that developed and commercialized specialty therapeutics for patients with hematologic, immunologic, and oncologic conditions. Founded in 2014 and headquartered in Illinois, United States, the company operated as a publicly traded entity on the NYSE under ticker BXLT and was characterized as a $6 billion global biopharmaceutical leader with more than 10,000 employees.

Baxalta's commercial portfolio centered on rare and serious disease therapeutics, with oncology as a strategic growth vertical. On July 23, 2015, the company acquired ONCASPAR (pegaspargase), a specialty biologic indicated for acute lymphoblastic leukemia, expanding its hematology/oncology franchise and reinforcing its positioning in orphan-indication therapeutics where clinical complexity and regulatory exclusivity support durable franchises.

The company monetized its portfolio through branded specialty pharmaceutical sales to hospitals, specialty pharmacies, and treatment centers, generating $6 billion in revenue at scale with 10,000+ employees. Baxalta was delisted from the NYSE following a corporate transaction, ending its standalone operating history and absorbing its assets and pipeline into a larger pharmaceutical parent.

Baxalta firmographics

Firmographics
Name
Baxalta
Website
https://baxalta.com
Company type
Private
Founded year
2014
Headcount range
5,001–10,000 employees
Short description
Baxalta was a $6 billion global biopharmaceutical company that developed and commercialized specialty therapeutics for hematology, immunology, and oncology conditions, serving patients and healthcare providers worldwide from its Illinois headquarters with 10,000+ employees.
Ownership category
akta.pro rank

Baxalta industry classification

Industry
Product category
Specialty Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro primary industry
Plasma Fractionation & Purification Manufacturing (HLAIAHAI)
akta.pro secondary industries
Plasma-Derived Therapeutics (immunoglobulins, albumin, clotting factors) (HLAAAAAI), Rare Oncology & Hematologic Malignancy Therapies (HLAIAIAC)

Keywords

  • Biopharmaceutical products
  • Rare disease therapies
  • Hematology treatments
  • Immunology products
  • Oncology biologics

Where Baxalta is headquartered

Location

Headquarters

HQ city
Illinois City
HQ country
United States
HQ region
North America

Markets served

Baxalta business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure

Baxalta product offering

Product offering

Core offering

Baxalta was a global biopharmaceutical company that developed, manufactured, and commercialized specialty biologic therapies for rare and underserved patient populations in hematology, immunology, and oncology. The company built a portfolio around hospital-administered biologic treatments such as ONCASPAR (pegaspargase) for acute lymphoblastic leukemia, distributing them to specialty healthcare providers worldwide.

Differentiator

Problem solved

Functional benefit

Products and services

  • ONCASPAR (pegaspargase) ONCASPAR (pegaspargase) is a biologic therapy used as a component of multi-agent chemotherapy regimens for patients with acute lymphoblastic leukemia (ALL). Following Baxalta's 2015 acquisition, it became part of the company's specialty hematology/oncology franchise distributed to hospitals and specialty oncology treatment centers.

Companies that use Baxalta

Customer profile

Ideal customer profiles1 record

Baxalta technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Baxalta partnerships and signals

Strategic signal

Expansion highlights4 records

Baxalta competitors and assessment

Company assessment

Direct peers

  • Alexion Pharmaceuticals: Alexion specialized in rare-disease therapeutics (complement-mediated diseases), making it a direct peer in the rare-disease specialty biopharmaceutical category.
  • CSL Behring: CSL Behring is the global leader in plasma-derived therapeutics, directly competing with Baxalta in immunoglobulins, clotting factors, and specialty plasma products.
  • Octapharma: Octapharma is one of the largest privately held plasma fractionators globally, competing directly with Baxalta in immunoglobulin and coagulation-factor markets.
  • Swedish Orphan Biovitrum (Sobi): Sobi is a European rare-disease biopharmaceutical company with significant overlap in hematology and immunology franchises, directly comparable to Baxalta's portfolio.
  • Shire plc: Shire was the direct acquirer of Baxalta in 2016 and operated in the same rare-disease and specialty biopharmaceutical space, with overlapping hematology, immunology, and rare-disease franchises.
  • Grifols: Grifols is a major plasma fractionator and specialty biopharmaceutical company with a directly overlapping plasma-derived therapeutics portfolio.
  • Bioverativ: Bioverativ focused on hemophilia and rare blood disorders before being acquired by Sanofi, directly overlapping Baxalta's hematology franchise.

Emerging players

  • BioMarin Pharmaceutical: BioMarin focuses on rare-disease therapeutics for serious genetic conditions, making it a comparable specialty biopharma peer with similar business-model dynamics.
  • Vertex Pharmaceuticals: Vertex develops specialty therapeutics for serious diseases including rare genetic disorders, sharing the high-priced, specialty-care commercial model of Baxalta.

Broad incumbents

  • Genzyme (Sanofi): Sanofi's Genzyme unit operates a broad rare-disease specialty portfolio with overlapping rare hematology and immunology capabilities, competing with Baxalta across multiple indications.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Baxalta social profiles

Digital presence

Baxalta financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Baxalta leadership team

Management profile

Number of profiles

Baxalta funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Baxalta M&A and investment

M&A and investment

M&A1 record

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Baxalta

What does Baxalta do?

Baxalta was a global biopharmaceutical company that developed, manufactured, and commercialized specialty biologic therapies for rare and underserved patient populations in hematology, immunology, and oncology. The company built a portfolio around hospital-administered biologic treatments such as ONCASPAR (pegaspargase) for acute lymphoblastic leukemia, distributing them to specialty healthcare providers worldwide.

When was Baxalta founded?

Baxalta was founded in 2014. It employs 5,001 to 10,000 people.

Where is Baxalta based?

Baxalta is headquartered in Illinois City, United States, in the North America region.

Who are Baxalta's main competitors?

Direct peers on record are Alexion Pharmaceuticals, CSL Behring, Octapharma, Swedish Orphan Biovitrum (Sobi), Shire plc, Grifols and Bioverativ. Emerging players are BioMarin Pharmaceutical and Vertex Pharmaceuticals. Genzyme (Sanofi) is listed as a broad incumbent.

Does Baxalta have an API?

No public API is recorded for Baxalta.

What industry is Baxalta in?

Baxalta's product category is Specialty Biopharmaceuticals. Its primary akta.pro industry code is HLAIAHAI, Plasma Fractionation & Purification Manufacturing, with a secondary code of HLAAAAAI, Plasma-Derived Therapeutics (immunoglobulins, albumin, clotting factors). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
LinkedInLack of Market Access Perspective Leaves Companies Paying Too Much for Pharmaceutical AssetsPharmaceutical companies often overpay for acquisitions due to the lack of market access considerations in their valuation models, leading to significant financial losses. A notable example is Shire's acquisition of Baxalta, where a 43% premium led to a nearly 50% drop in Shire's stock value post-acquisition. To avoid similar pitfalls, integrating market access expertise into M&A evaluations is essential for making risk-adjusted financial decisions.openPR.comMyocardial Ischemia Market Rapidly Growing in Healthcare, Competitive Landscape, Potential Revenue by Baxalta Incorporated, Bayer AG, Cellmid, CohBar, NoNO, Symic Biomedical, ViroMed and Global ForecaBusiness Industry Reports published a market research report on the global Myocardial Ischemia market, forecasting healthy growth and a high demand for treatments through 2022. The analysis identifies key regional trends, noting North America's leading position due to an aging population, while Europe faces challenges from drug patent expirations and Japan experiences stagnation. The report profiles major industry players including Baxalta Incorporated, Bayer AG, and ViroMed among others.PR NewswireShire Announces The Pricing Terms And Increase In The Maximum Tender Amount Of The Previously Announced Cash Tender Offers For Certain Outstanding NotesShire plc and its subsidiaries Baxalta Incorporated and Shire Acquisitions Investments Ireland DAC announced the pricing terms for their previously announced cash tender offers to repurchase multiple series of senior notes, while increasing the Aggregate Maximum Purchase Amount from $2.25 billion to approximately $2.33 billion. The tender offers received strong participation, with the aggregate principal amount tendered exceeding the maximum purchase amount, resulting in proration of approximately 70.237% for all Priority 1 notes. The early settlement date is expected to be September 11, 2018, with the offers scheduled to expire on September 21, 2018.PR NewswireShire Announces Cash Tender Offers for up to $2,250,000,000 Outstanding Principal Amount of NotesShire plc and its subsidiaries Baxalta Incorporated and Shire Acquisitions Investments Ireland DAC announced cash tender offers to purchase up to $2.25 billion aggregate principal amount of outstanding senior notes issued by those entities, covering five series of notes with maturities ranging from 2020 to 2046. The tender offers are conditional upon Shire closing the sale of its Oncology business and include early tender premiums of $30 per $1,000 principal amount. The offers are set to expire on September 21, 2018, with holders able to withdraw tenders until September 7, 2018.PR NewswireIntravenous Immunoglobulin Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2024ReportBuyer has published a market research report on the global Intravenous Immunoglobulin (IVIG) industry, covering analysis from 2017 to 2024. The report profiles key market players including Baxalta Incorporated, CSL Behring LLC, and Grifols S.A., while detailing market segmentation by indication, end-user, and geography.PR NewswireBurson-Marsteller Strengthens Corporate and Financial Practice with Three New Senior AppointmentsBurson-Marsteller announced the hiring of Geoffrey Mogilner, Neil Barman, and Kona Barrasso as senior leaders in its Corporate and Financial Practice to expand capabilities in investor relations and change management. These appointments aim to enhance the firm's service offerings for C-suite clients facing critical business decisions in financial communications and corporate positioning. The hires bring extensive experience from previous roles at companies such as Baxalta, Deloitte, and A.T. Kearney.PR NewswireShire to Highlight Focus on Rare Disease Innovation at Investor DayShire plc announced an Investor Day event scheduled for November 10, 2016, in New York City, to present its growth opportunities and rare disease innovation pipeline to the investment community. The company will highlight the benefits derived from its acquisition of Baxalta and discuss specific late-stage clinical programs in hematology, immunology, and neuroscience. No new material information is expected to be disclosed during this presentation.PR NewswireHemophilia Drugs Market to Grow at 4.76% CAGR to 2020According to a 2016 market research report, the global hemophilia drugs market is forecast to grow at a compound annual growth rate (CAGR) of 4.76% during the period 2016-2020. The report identifies long-acting drugs and recombinant therapies as key growth drivers, with the Americas accounting for the highest revenue share in 2015 and expected to maintain market dominance through 2020. Key players in the market include Baxalta, Bayer, CSL Behring, Novo Nordisk, and Pfizer, alongside numerous other pharmaceutical companies developing hemophilia treatments.PR NewswireShire Prices Public Offering of Senior NotesShire plc's subsidiary, Shire Acquisitions Investments Ireland Designated Activity Company, priced an inaugural public offering of $12.1 billion aggregate principal amount of senior notes across four tranches, expected to close on September 23, 2016. The company intends to use the net proceeds to fully repay bridge financing facilities that were used to fund its acquisition of Baxalta Incorporated, and for general corporate purposes. The notes consist of $3.3 billion at 1.900% due 2019, $3.3 billion at 2.400% due 2021, $2.5 billion at 2.875% due 2023, and $3.0 billion at 3.200% due 2026.GlobeNewswireCoherus BioSciences Reports Second Quarter 2016 Financial and Operating ResultsCoherus BioSciences reported Q2 2016 revenue of $14.1 million and a net loss of $70 million. The company received a $30 million milestone payment from Baxalta and advanced its biosimilar pipeline, including a positive Phase 2b study for CHS-131. It also announced a public offering of 4.025 million shares at $18 per share.